Efficacy of modified levamisole adjuvant on inactivated virus vaccine
Efficacy of modified levamisole adjuvant on inactivated virus vaccine
复制标题
改良左旋咪唑佐剂对灭活病毒疫苗的功效
DOI：
10.1089/vim.2006.19.525
复制
发表时间：
2006-06-01
期刊：
影响因子：
2.2
通讯作者：
Wang, Bin
中科院分区：
文献类型：
--
作者：
Yin, Jiangmei;Jin, Huali;Wang, Bin
以新城疫病毒(NDV)为模型病原，研究了改良左旋咪唑佐剂(LMS+)对小鼠和鸡的免疫效果。与油佐剂相比，在LMS+中灭活的新城疫病毒诱导了显著更高的辅助性T细胞1型应答，表现为更高水平的白细胞介素2、干扰素-γ、T细胞增殖和迟发型超敏反应，而不牺牲小鼠的免疫球蛋白生成水平。此外，LMS+的疫苗可增加MHC和共刺激分子的表达以及CD11c(+)树突状细胞的数量，提示对LMS+的更好应答部分是通过树突状细胞的成熟和MHC-抗原递呈和共刺激的激活来实现的。此外，该配方在1000 ELD50(50%鸡蛋致死剂量)下用致死剂量的新城疫病毒F48E9株攻击后，对鸡提供100%的保护。这些结果表明，改良的LMS+佐剂可以改善灭活疫苗的体液和细胞免疫应答，是一种有效的灭活疫苗。
To improve efficacy, especially for the cell-mediated response to inactivated viral vaccines, a modified levamisole (LMS) adjuvant formulation, designated LMS+, was evaluated for its efficacy in mice and chickens, using Newcastle Disease Virus (NDV) as a model pathogen. Compared with oil adjuvant, the killed NDV in LMS+ induced a significantly higher helper T cell type 1 response, as shown by higher levels of interleukin-2, interferon-gamma, T cell proliferation, and delayed-type hypersensitivity responses, without sacrificing the level of IgG production in mice. In addition, vaccine in LMS+ formulation increased the expression of MHC and costimulatory molecules as well as the number of CD11c(+) dendritic cells, suggesting that the better response to the LMS+ formulation occurs partly via the maturation of dendritic cells and activation of MHC-antigen presentation and costimulation. Furthermore, this formulation provides 100% protection in chickens after challenge with a lethal dose of virulent NDV strain F48E9 at 1000 ELD50 (50% egg lethal dose). These results demonstrated that modified LMS+ adjuvant could be used to improve both humoral and cell-mediated responses for inactivated viral vaccines and its development as an effective inactivated viral vaccine is warranted.